MENA patients and their wellbeing are why we exist. Lumecure is the market-access bridge for international manufacturers — carrying innovative medicines, biosimilars, and medical technology into the region's health systems, ensuring fewer people wait for care that already exists.
A UAE-based pharmaceutical sourcing and supply company, built on one conviction: no patient should go without a treatment that already exists. For international manufacturers with limited MENA exposure, we are the partner of choice on the ground — fluent in the ministries, the tenders, and the culture of doing business in the region.
We work where regulatory intelligence, supply-chain discipline, and clinical purpose meet — sourcing innovative medicines, biosimilars, and medical equipment from qualified global manufacturers, and commercializing them where patient needs are still unmet.
The categories GCC health ministries, hospitals, and clinics rely on — and the clearest route into the region for the international manufacturers who make them.
Prescription medicines, generics, biosimilars, biologics, and OTC drugs — our core focus. We prioritise therapies where a verified generic or biosimilar can reach GCC patients sooner.
Instruments and devices for hospitals, surgical theatres, and diagnostics — sourced from CE- and FDA-cleared manufacturers with established GCC distribution.
Pharmacy-channel skincare, dermacosmetics, and medical-grade preparations for dermatology clinics, aesthetic practices, and pharmacies across the GCC — a fast-growing area of patient care.
Behind every product is a patient waiting. We don't distribute from a catalogue — we start with unmet clinical need, identified through data: a gap in a tender list, an originator therapy now open to generics, a fragile single-source supply. Then we bring the sourcing, regulatory, and manufacturer expertise to close it responsibly.
We analyse MOH tenders, drug registries, and formularies across the GCC and Levant to find therapies where a verified generic or biosimilar is viable — but not yet reaching patients.
Verified therapies reach GCC distributors, tenders, or licensed importers — structured for compliant, traceable, dependable supply.
We engage qualified generic, biosimilar, and device makers — mainly Europe, Turkey, the US, India, and South Korea.
Every therapy is checked for regulatory status, dossier completeness, GCC registration pathway, and supplier quality.
From 2025 to 2030, an unprecedented wave of drug patents expires worldwide — opening generic and biosimilar versions of the most-prescribed medicines on earth. Treatments once out of reach become attainable. The only question is how fast health systems bring them in.
Europe and the US are adopting biosimilars of major oncology and anti-inflammatory biologics in real time. GCC and Levant systems still depend on originators — lagging global patent events by 3 to 5 years.
That lag is measured in patients. The biosimilar exists, is approved, is available — yet the GCC patient still can't reach it, because no trusted partner has brought it through the right channel.
That's why Lumecure exists — the bridge between global availability and the person still waiting.
“Geography should never decide who gets treated. Somewhere in the world, the cure already exists — our job is to bring it within reach.”
We founded Lumecure on a simple observation: the medicines our region waits for are already being made. What’s missing is the bridge — a partner who knows the manufacturers on one side, and the ministries, tenders, and culture of this region on the other. That is the company we are building.
To the international manufacturers we represent: you built the innovation; we’ll build your path into MENA. To the health systems we serve: your patients are our purpose — every product we pursue begins and ends with them.
We partner with health ministries, state hospital networks, and licensed distributors across the Gulf and Levant. Business in this region is built on trust, presence, and relationships earned over years. We bring all three, working alongside the people who decide what reaches patients.
Most distributors supply what they already hold. We start from what patients and health systems need — and go find it. For the manufacturers who make it, we are the partner of choice for MENA market access.
Our leadership built their careers inside GCC and Levant pharma and international distribution — not adjacent to it. The relationships, market knowledge, and supplier networks are 25+ years in the making.
We know GCC and Levant MOH tenders first-hand — how bids are scored, products registered, and supply agreements formed. Institutional practice, not research.
We start with the gap, not the catalogue. Every therapy in our pipeline came from tender data, registries, or health-system insight — never a supplier's stock list.
Tied to no single manufacturer or distributor, we partner with principals on quality, regulatory rigour, and reliability. Health systems that work with us reach the widest range of verified alternatives.
One partner, end to end: from the first market assessment to medicines reaching patients. Everything an international manufacturer needs to enter the region — under a single, accountable relationship.
Tender data, drug registries, and unmet-need mapping across the GCC and Levant — an evidence-based case before any commitment.
GCC and Levant MOH pathways, dossier preparation, and product registration — managed end to end.
MOH tender participation and institutional procurement channels, navigated with first-hand experience.
Licensed importers and cold-chain-capable partners across the region — compliant, traceable, dependable supply.
Post-market safety monitoring and regulatory obligations, upheld across every market we serve.
Launch, medical education, KOL engagement, and patient access — carried through to the clinic.
We work only with WHO-GMP, EMA, or US-FDA-compliant manufacturing partners.
Registration-ready dossiers and full compliance with GCC and Levant health-authority requirements.
Active post-market safety monitoring for every product we bring into the region.
A documented, auditable chain from manufacturer to institution — no exceptions.